Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

First International Summit on Interventional Pharmacoeconomics

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Focus on Optimized Dosing of Ibrutinib Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

May

Today In Oncology

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Related Videos

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Focus on Optimized Dosing of Ibrutinib Panel Discussion

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Targeted Therapies Drive Long-Term Decline in Multiple Myeloma Mortality in the United States

Patient-Reported Outcomes Support Niraparib Maintenance in Advanced Ovarian Cancer Regardless of Homologous Recombination Deficiency Status

FDA Approves Antibody-Drug Conjugate for Triple-Negative Breast Cancer

Preclinical Studies Evaluate Mezigdomide for T-Cell Dysfunction in Multiple Myeloma

AI Avatar–Based Education Leads to Improved Patient Understanding of Radiation Treatment Plans